![]() |
CZECH MEDICAL ASSOCIATION J. Ev. PURKYNĚ |
Journals - Article | |
![]() |
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Česky / Czech version | Vnitř. Lék., 49, 2003, No. 3, p. 222 - 226 |
Plasminogen Activator Inhibitor (PAI-1), Ischaemic Heart Disease
and Diabetes Mellitus Olexa P.1, Olexová M.2 1IV. interná klinika Lekárskej fakulty UPJŠ a Fakultnej nemocnice L. Pasteura, Košice, Slovenská republika, prednosta prof. MUDr. Ivan Tkáč, Ph.D.2Oddelenie klinickej imunológie a alergológie Fakultnej nemocnice L. Pasteura, Košice, Slovenská republika, prednosta prim. MUDr. Jana Kiseľová |
|
Summary: The classic risk factors can only in part explain the increased incidence and extent of coronary
artery disease. Plasminogen activator inhibitor type-1 (PAI-1), the main human regulator of endogenous
fibrinolysis, is considered to be an important cardiovascular risk factor. The article discuss
the current knowledge of the PAI-1 importance and role in the in the pathogenesis of
atherosclerosis and mechanisms of its synthesis predominantly in patients with coronary artery
disease associated with diabetes mellitus type 2. It explaines contributions of PAI-1 to the pathophysiologic
links between diabetes mellitus and cardiovascular diseases and shows current
therapeutic interventions normalising PAI-1 activity, their beneficial effect on prognosis and
course of coronary artery disease.
|
|
Order this issue
|
BACK TO CONTENTS | ||
| HOME PAGE | CODE PAGE | CZECH VERSION | |
© 1998 - 2008 CZECH MEDICAL ASSOCIATION J. E. PURKYNĚ |
Created by: NT Servis, s.r.o., hosted by P.E.S. consulting, s.r.o. |
WEBMASTER |